Characterizing the mechanisms of progression in multiple sclerosis: Evidence and new hypotheses for future directions

Archives of Neurology

Volumn 62, Issue 9, 2005, Pages 1345-1356

  Frohman, E M ^a   Filippi, M ^b   Stuve, O ^c   Waxman, S G ^d   Corboy, J ^e   Phillips, J T ^f   Lucchinetti, C ^g   Wilken, J ^h   Karandikar, N ^a   Hemmer, B ^c   Monson, N ^a   De Keyser, J ⁱ   Hartung, H ^c   Steinman, L ^j   Oksenberg, J R ^k   Cree, B A C ^k   Hauser, S ^k   Racke, M K ^a,k  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f Texas Neurology   (United States)

^g MAYO CLINIC   (United States)

^h DEPARTMENT OF VETERANS AFFAIRS   (United States)

ⁱ UNIVERSITY OF GRONINGEN   (Netherlands)

^j STANFORD UNIVERSITY   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; CD4 ANTIGEN; CD40 LIGAND; CD8 ANTIGEN; CYCLIC AMP; CYTOKINE; GAMMA INTERFERON; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 17; LIPOPROTEIN; MYELIN; MYELIN ASSOCIATED GLYCOPROTEIN; OKT 4; OSTEOPONTIN; SODIUM CHANNEL; TUMOR NECROSIS FACTOR ALPHA;

ASTROCYTE; B LYMPHOCYTE; CELL FUNCTION; CELL TRANSFER; CELLULAR IMMUNITY; CENTRAL NERVOUS SYSTEM; CHOLESTEROL SYNTHESIS; CLINICAL FEATURE; CYTOKINE PRODUCTION; DEMYELINATION; DISEASE COURSE; DRUG MECHANISM; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; HUMORAL IMMUNITY; IMMUNOPATHOLOGY; INFLAMMATION; MEDICAL RESEARCH; MULTIPLE SCLEROSIS; NERVE FIBER; NEURORADIOLOGY; NONHUMAN; PATHOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RELAPSE; REMYELINIZATION; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH2 CELL; WHITE MATTER;

DISEASE PROGRESSION; GENETICS; HUMANS; IMMUNE SYSTEM; MODELS, BIOLOGICAL; MULTIPLE SCLEROSIS; NEUROSCIENCES;

EID: 25144520110     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.62.9.1345     Document Type: Review

References (140)

1. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 1998;338:278-285.
2. Bitsch A, Schuchardt J, Bunkowski S, Kuhlmann T, Brück W. Acute axonal injury in multiple sclerosis: correlation with demyelination and inflammation. Brain. 2000;123:1174-1183.
3. Kornek B, Storch MK, Weissert R, et al. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol. 2000;157:267-276.
4. Rivera-Quinones C, McGavern D, Schmelzer J, Hunter S, Low P, Rodriguez M. Absence of neurological deficits following extensive demyelination in a class 1-deficient murine model of multiple sclerosis. Nat Med. 1998;4:187-193.
5. Smith KJ, Kapoor R, Hall SM, Davies M. Electrically active axons degenerate when exposed to nitric oxide. Ann Neurol. 2001;49:470-476.
6. Yin X, Crawford TO, Griffin JW, et al. Myelin-associated glycoprotein is a myelin signal that modulates the caliber of myelinated axons. J Neurosci. 1998;18:1953-1962.
7. Frohman EM, Stüve O, Havrdova E, et al. Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectations. Arch Neurol. 2005;62 In press.
8. Lovett-Racke AE, Trotter JL, Lauber J, Perrin PJ, June CH, Racke MK. Decreased dependence of myelin basic protein-reactive T cells on CD28-mediated costimulation in multiple sclerosis patients: a marker of activated/memory T cells. J Clin Invest. 1998;101:725-730.
9. Scholz C, Patton KT, Anderson DE, Freeman GJ, Hafler DA. Expansion of autoreactive T cells in multiple sclerosis is independent of exogenous B7 costimulation. J Immunol. 1998;160:1532-1538.
10. van Oosten BW, Lai M, Hodgkinson S, et al. Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial. Neurology. 1997;49:351-357.
11. Rep MH, van Oosten BW, Roos MT, Ader HJ, Polman CH, van Lier RA. Treatment with depleting CD4 monoclonal antibody results in a preferential loss of circulating naïve T cells but does not affect IFN-gamma secreting TH1 cells in humans. J Clin Invest. 1997;99:2225-2231.
12. Balashov KE, Smith DR, Khoury SJ, Hafler DA, Weiner HL. Increased IL-12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand. Proc Natl Acad Sci U S A. 1997;94:599-603.
13. Moldovan IR, Rudick RA, Cotleur AC, et al. Interferon gamma responses to myelin peptides in multiple sclerosis correlate with a new clinical measure of disease progression. J Neuroimmunol. 2003;141:132-140.
14. Killestein J, Kalkers NF, Meilof JF, Barkhof F, van Lier RAW, Polman CH. TNFa production by CD4+ T cells predicts long-term increase in lesion load on MRI in MS. Neurology. 2001;57:1129-1131.
15. Babbe H, Roers A, Waisman A, et al. Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med. 2000;192:393-404.
16. Skulina C, Schmidt S, Dornmair K, et al. Multiple sclerosis: brain-infiltrating CD8+ T cells persist as clonal expansions in the cerebrospinal fluid. Proc Natl Acad Sci U S A. 2004;101:2428-2433.
17. Tsuchida T, Parker KC, Turner RV, McFarland HF, Coligan JE, Biddison WE. Autoreactive CD8+ T-cell responses to human myelin protein-derived peptides. Proc Natl Acad Sci U S A. 1994;91:10859-10863.
18. Crawford MP, Yan SX, Ortega S, et al. High prevalence of autoreactive neuroantigen-specific CD8+ T cells in multiple sclerosis revealed by novel flow cytometric assay. Blood. 2004;103:4222-4231.
19. Allegretta M, Nicklas JA, Sriram S, Albertini RJ. T cells responsive to myelin basic protein in patients with multiple sclerosis. Science. 1990;247:718-721.
20. Karandikar NJ, Crawford MP, Yan X, et al. Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis. J Clin Invest. 2002;109:641-649.
21. Koh DR, Fung-Leung WP, Ho A, Gray D, Acha-Orbea H, Mak TW. Less mortality but more relapses in experimental allergic encephalomyelitis in CD8-/-mice. Science. 1992;256:1210-1213.
22. Antel J, Bania M, Noronha A, Neely S. Defective suppressor cell function mediated by T8+ cell lines from patients with progressive multiple sclerosis. J Immunol. 1986;137:3436-3439.
23. Shlomchik MJ, Craft JE, Mamula MJ. From T to B and back again: positive feedback in systemic autoimmune disease. Nat Rev Immunol. 2001;1:147-153.
24. Cepok S, Jacobsen M, Schock S, et al. Patterns of cerebrospinal fluid pathology correlate with disease progression in multiple sclerosis. Brain. 2001;124:2169-2176.
25. Wolf SD, Dittel BN, Hardarottir F, Janeway CA Jr. Experimental autoimmune encephalomyelitis in genetically B cell-deficient mice. J Exp Med. 1996;184:2271-2278.
26. Levin MC, Lee SM, Kalume F, et al. Autoimmunity due to molecular mimicry as a cause of neurological disease. Nat Med. 2002;8:509-513.
27. Shirai A, Aoki I, Otani M, Mond JJ, Klinman DM. Treatment with dextran-conjugated anti-IgD delays the development of autoimmunity in MRL-lpr/lpr mice. J Immunol. 1994;153:1889-1894.
28. Nemazee D, Hogquist KA. Antigen receptor selection by editing or downregulation of V(D)J recombination. Curr Opin Immunol. 2003;15:182-189.
29. Owens G, Ritchie A, Burgoon M, Williamson R, Corboy J, Gilden D. Single cell repertoire analysis demonstrates clonal expansion is prominent feature of the B cell response in multiple sclerosis spinal fluid. J Immunol. 2003;171:2725-2733.
30. Anolik J, Sanz I, Looney RJ. B cell depletion therapy in systemic lupus erythematosus. Curr Rheumatol Rep. 2003;5:350-356.
31. Lehmann PV, Forsthuber T, Miller A, Sercarz EE. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature. 1992;358:155-157.
32. Tian J, Gregori S, Adorini L, Kaufman DL. The frequency of high avidity T cells determines the hierarchy of determinant spreading. J Immunol. 2001;166:7144-7150.
33. Tuohy VK, Yu M, Weinstock-Guttman B, Kinkel RP. Diversity and plasticity of self recognition during the development of multiple sclerosis. J Clin Invest. 1997;99:1682-1690.
34. Yu M, Kinkel RP, Weinstock-Guttman B, Cook DJ, Tuohy VK. HLA-DP: a class II restriction molecule involved in epitope spreading during the development of multiple sclerosis. Hum Immunol. 1998;59:15-24.
35. O'Garra A. Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity. 1998;8:275-283.
36. Woodland DL, Dutton RW. Heterogeneity of CD4(+) and CD8(+) T cells. Curr Opin Immunol. 2003;15:336-342.
37. Seder RA, Paul WE. Acquisition of lymphokine-producing phenotype by CD4+ T cells. Annu Rev Immunol. 1994;12:635-673.
38. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today. 1996;17:138-146.
39. Sharief MK, Hentges R. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N Engl J Med. 1991;325:467-472.
40. Comabella M, Balashov K, Issazadeh S, Smith D, Weiner HL, Khoury SJ. Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy. J Clin Invest. 1998;102:671-678.
41. Steimle V, Siegrist CA, Mottet A, Lisowska-Grospierre B, Mach B. Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA. Science. 1994;265:106-109.
42. Panitch HS, Hirsch RL, Haley AS, Johnson KP. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet. 1987;1:893-895.
43. Duda PW, Schmied MC, Cook SL, Krieger JI, Hafler DA. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J Clin Invest. 2000;105:967-976.
44. Youssef S, Stuve O, Patarroyo JC, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature. 2002;420:78-84.
45. Bielekova B, Goodwin B, Richert N, et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med. 2000;6:1167-1175.
46. Kappos L, Comi G, Panitch H, et al; the Altered Peptide Ligand in Relapsing MS Study Group. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomised phase II trial. Nat Med. 2000;6:1176-1182.
47. Langrish CL, Chen Y, Blumanschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med. 2005;201:233-240.
48. Vajkoczy P, Laschinger M, Engelhardt B. Alpha 4-integrin-VCAM-1 binding mediates G protein-independent capture of encephalitic T cell blasts to CNS white matter microvessels. J Clin Invest. 2001;108:557-565.
49. Yednock TA, Cannon L, Fritz L, et al. Prevention of experimental allergic encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature. 1992;356:63-66.
50. Walters CE, Pryce G, Hankey DJ, et al. Inhibition of Rho GTPases with protein prenyltransferase inhibitors prevents leukocyte recruitment to the central nervous system and attenuates clinical signs of disease in an animal model of multiple sclerosis. J Immunol. 2002;168:4087-4094.
51. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2003;348:15-23.
52. De Keyser J, Wilczak N, Leta R, Streetland C. Astrocytes in multiple sclerosis lack beta-2 adrenergic receptors. Neurology. 1999;53:1628-1633.
53. De Keyser J, Zeinstra E, Frohman E. Are astrocytes central players in the pathophysiology of multiple sclerosis? Arch Neurol. 2003;60:132-136.
54. Nakamura A, Johns EJ, Imaizumi A, Abe T, Kohsaka T. Regulation of tumour necrosis factor and interleukin-6 gene transcription by beta2-adrenoceptor in the rat astrocytes. J Neuroimmunol. 1998;88:144-153.
55. Sanchez-Abarca LI, Tabernero A, Medina JM. Oligodendrocytes use lactate as a source of energy and as a precursor of lipids. Glia. 2001;36:321-329.
56. Tokita Y, Keino H, Matsui F, et al. Regulation of neuregulin expression in the injured rat brain and cultured astrocytes. J Neurosci. 2001;21:1257-1264.
57. Viehover A, Miller RH, Park SK, Fischbach G, Vartanian T. Neuregulin: an oligodendrocyte growth factor absent in active multiple sclerosis lesions. Dev Neurosci. 2001;23:377-386.
58. Ransom BR, Waxman SG, Davis PK. Anoxic injury of CNS white matter: protective effect of ketamine. Neurology. 1990;40:1399-1404.
59. Stys PK, Ransom BR, Waxman SG, Davis PK. Role of extracellular calcium in anoxic injury of mammalian central white matter. Proc Natl Acad Sci U S A. 1990;87:4212-4216.
60. Stys PK, Waxman SG, Ransom BR. Ionic mechanisms of anoxic injury in mammalian CNS white matter: role of Na+-Ca2+ exchanger. J Neurosci. 1992;12:430-439.
61. Lassmann H. Hypoxia-like tissue injury as a component of multiple sclerosis lesions. J Neurol Sci. 2003;206:187-191.
62. Kapoor R, Davies M, Blaker PA, et al. Blockers of sodium and calcium entry protect axons from nitric oxide mediated degeneration. Ann Neurol. 2003;53:174-180.
63. Craner MJ, Newcombe J, Black JA, Hartle C, Cuzner ML, Waxman SG. Molecular changes in neurons in MS: altered axonal expression of Nav1.2 and Nav1.6 sodium channels and Na+/C2+ exchanger in the human CNS. Proc Natl Acad Sci U S A. 2004;101:8168-8173.
64. Lo AC, Saab CY, Black JA, Waxman SG. Phenytoin protects spinal cord axons and preserves axonal conduction and neurological function in a model of neuroinflammation in vivo. J Neurophysiol. 2003;90:3566-3571.
65. Waxman SG. NO and the axonal death cascade. Ann Neurol. 2003;53:150-154.
66. Kim JE, Li S, GrandPre T, Qiu D, Strittmatter SM. Axon regeneration in young adult mice lacking Nogo-A/B. Neuron. 2003;38:187-199.
67. Domeniconi M, Cao Z, Spencer T, et al. Myelin-associated glycoprotein interacts with the Nogo66 receptor to inhibit neurite outgrowth. Neuron. 2002;35:283-290.
68. Cai D, Deng K, Mellado W, Le J, Ratan RR, Filbin MT. Arginase I and polyamines act downstream from cyclic AMP in overcoming inhibition of axonal growth MAG and myelin in vitro. Neuron. 2002;35:711-719.
69. Kappos L, Moeri D, Radue EW, et al. Predictive value of gadolinium-enhanced MRI for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Lancet. 1999;353:964-969.
70. Filippi M, Arnold DL, Comi G, eds. Magnetic Resonance Spectroscopy in Multiple Sclerosis. Milan, Italy: Springer-Verlag; 2001.
71. Filippi M, Bozzali M, Rovaris M, et al. Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain. 2003;126:433-437.
72. Rovaris M, Bozzali M, Santuccio G, et al. In vivo assessment of the brain and cervical cord pathology of patients with primary progressive multiple sclerosis. Brain. 2001;124:2540-2549.
73. Bozzali M, Cercignani M, Sormani MP, Comi G, Filippi M. Quantification of brain gray matter damage in different MS phenotypes by use of diffusion tensor MR imaging. AJNR Am J Neuroradiol. 2002;23:985-988.
74. Filippi M, Rocca MA. Disturbed function and plasticity in multiple sclerosis as gleaned from functional magnetic resonance imaging. Curr Opin Neurol. 2003;16:275-282.
75. Chabas D, Baranzini S, Mitchell D, et al. The influence of the pro-inflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science. 2001;294:1731-1735.
76. Lock C, Hermans G, Pedotti R, et al. Gene microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med. 2002;8:500-508.
77. Steinman L, Zamvil S. Transcriptional analysis of targets in multiple sclerosis. Nat Rev Immunol. 2003;3:483-493.
78. Vogt M, Lopatinskaya L, Smits M, Polman CH, Nagelkerken L. Elevated osteopontin levels are associated with disease activity in relapsing-remitting MS patients. Ann Neurol. 2003;53:819-822.
79. Vollmer T, Key L, Durkalski V, et al. Oral simvastatin in relapsing-remitting multiple sclerosis. Lancet. 2004;363:1607-1608.
80. Doolittle TH, Myers RH, Lehrich JR, et al. Multiple sclerosis sibling pairs: clustered onset and familial predisposition. Neurology. 1990;40:1546-1552.
81. Weinshenker BG, Bulman D, Carriere W, Baskerville J, Ebers GC. A comparison of sporadic and familial multiple sclerosis. Neurology. 1990;40:1354-1358.
82. Barcellos LF, Oksenberg JR, Green AJ, et al. Genetic basis for clinical expression in multiple sclerosis. Brain. 2002;125:150-158.
83. Bulman DE, Sadovnick AD, Ebers GC. Age of onset in siblings concordant for multiple sclerosis. Brain. 1991;114:937-950.
84. Butterfield RJ, Blankenhorn EP, Roper RJ, Zachary JF, Doerge RW, Teuscher C. Identification of genetic loci controlling the characteristics and severity of brain and spinal cord lesions in experimental allergic encephalomyelitis. Am J Pathol. 2000;157:637-645.
85. Mann CL, Davies MB, Boggild MD, et al. Glutathione S-transferase polymorphisms in MS: their relationship to disability. Neurology. 2000;54:552-557.
86. Schrijver HM, Crusius JB, Uitdehaag BM, et al. Association of interleukin-lbeta and interleukin-1 receptor antagonist genes with disease severity in MS. Neurology. 1999;52:595-599.
87. Kantarci OH, Atkinson EJ, Hebrink DD, McMurray CT, Weinshenker BG. Association of two variants in IL-1beta and IL-1 receptor antagonist genes with multiple sclerosis. J Neuroimmunol. 2000;106:220-227.
88. Sciacca FL, Ferri C, Vandenbroeck K, et al. Canal, bi., and Grimaldi, L. M. Relevance of interleukin 1 receptor antagonist intron 2 polymorphism in Italian MS patients. Neurology. 1999;52:1896-1898.
89. Feakes R, Sawcer S, Broadley S, et al. Interleukin 1 receptor antagonist (IL-lra) in multiple sclerosis. J Neuroimmunol. 2000;105:96-101.
90. Barcellos LF, Schito AM, Rimmler JB, et al . Multiple Sclerosis Genetics Group; CC-chemokine receptor 5 polymorphism and age of onset in familial multiple sclerosis. Immunogenetics. 2000;51:281-288.
91. Kantor R, Bakhanashvili M, Achiron A. A mutated CCR5 gene may have favorable prognostic implications in MS. Neurology. 2003;61:238-240.
92. Sellebjerg F, Madsen HO, Jensen CV, Jensen J, Garred P. CCR5 delta32, matrix metalloproteinase-9 and disease activity in multiple sclerosis. J Neuroimmunol. 2000;102:98-106.
93. Haase CG, Schmidt S, Faustmann PM. Frequencies of the G-protein beta3 subunit C825T polymorphism and the delta 32 mutation of the chemokine receptor-5 in patients with multiple sclerosis. Neurosci Lett. 2002;330:293-295.
94. Schreiber K, Otura AB, Ryder LP, et al. Disease severity in Danish multiple sclerosis patients evaluated by MRI and three genetic markers (HLA-DRBl* 1501, CCR5 deletion mutation, apolipoprotein E). Mult Scler. 2002;8:295-298.
95. Caillier S, Barcellos LF, Baranzini SE, et al. Osteopontin polymorphisms and disease course in multiple sclerosis. Genes Immun. 2003;4:312-315.
96. Niino M, Kikuchi S, Fukazawa T, Yabe I, Tashiro K. Genetic polymorphisms of osteopontin in association with multiple sclerosis in Japanese patients. J Neuroimmunol. 2003;136:125-129.
97. Hensiek AE, Roxburgh R, Meranian M, et al. Osteopontin gene and clinical severity of multiple sclerosis. J Neurol. 2003;250:943-947.
98. Vandenbroeck K, Martino G, Marrosu M, et al. Occurrence and clinical relevance of an interleukin-4 gene polymorphism in patients with multiple sclerosis. J Neuroimmunol. 1997;76:189-192.
99. Kantarci OH, Schaefer-Klein JL, Hebrink DD, et al. A population-based study of IL4 polymorphisms in multiple sclerosis. J Neuroimmunol. 2003;137:134-139.
100. Engell T, Raun NE, Thomsen M, Platz P. HLA and heterogeneity of multiple sclerosis. Neurology. 1982;32:1043-1046.
101. Madigand M, Oger JJ, Fauchet R, Sabouraud O, Genetet B. HLA profiles in multiple sclerosis suggest two forms of disease and the existence of protective haplotypes. J Neurol Sci. 1982;53:519-529.
102. Duquette P, Decary F, Pleines J, et al. Clinical sub-groups of multiple sclerosis in relation to HLA: DR alleles as possible markers of disease progression. Can J Neurol Sci. 1985;12:106-110.
103. de la Concha EG, Arroyo R, Crusius JB, et al. Combined effect of HLA-DRB 1 * 1501 and interleukin-1 receptor antagonist gene allele 2 in susceptibility to relapsing/remitting multiple sclerosis. J Neuroimmunol. 1997;80:172-178.
104. Celius EG, Harbo HF, Egeland T, Vartdal F, Vandvik B, Spurkiand A. Sex and age at diagnosis are correlated with the HLA-DR2, DQ6 haplotype in multiple sclerosis. J Neurol Sci. 2000;178:132-135.
105. Masterman T, Ligers A, Olsson T, Andersson M, Olerup O, Hiller J. HLA-DR15 is associated with lower age at onset in multiple sclerosis. Ann Neurol. 2000;48:211-219.
106. Hensiek AE, Sawcer SJ, Feakes R, et al. HLA-DR 15 is associated with female sex and younger age at diagnosis in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2002;72:184-187.
107. Poser S, Ritter G, Bauer HJ, Grosse-Wilde H, Kuwert EK, Raun NE. HLA-antigens and the prognosis of multiple sclerosis. J Neurol. 1981;225:219-221.
108. Runmarker B, Martinsson T, Wahlstrom J, Andersen O. HLA and prognosis in multiple sclerosis. J Neurol. 1994;241:385-390.
109. Weinshenker BG, Santrach P, Bissonet AS, et al. Major histocompatibility complex class II alleles and the course and outcome of MS: a population-based study. Neurology. 1998;51:742-747.
110. McDonnell GV, Mawhinney H, Graham CA, Hawkins SA, Middleton D. A study of the HLA-DR region in clinical subgroups of multiple sclerosis and its influence on prognosis. J Neurol Sci. 1999;165:77-83.
111. Villoslada P, Barcellos LF, Rio J, et al. The HLA locus and multiple sclerosis in Spain: role in disease susceptibility, clinical course and response to interferon-beta. J Neuroimmunol. 2002;130:194-201.
112. Kira J, Kanai T, Nishimura Y, et al. Western versus Asian types of multiple sclerosis: immunogenetically and clinically distinct disorders. Ann Neurol. 1996;40:569-574.
113. Hauser SL, Oksenberg JR, Lincoln R, et al; Optic Neuritis Study Group. Interaction between HLA-DR2 and abnormal brain MRI in optic neuritis and early MS. Neurology. 2000;54:1859-1861.
114. Olerup O, Hillert J, Fredrikson S, et al. Primarily chronic progressive and relapsing/remitting multiple sclerosis: two immunogenetically distinct disease entities. Proc Natl Acad Sci U S A. 1989;86:7113-7117.
115. Kantarci OH, de Andrade M, Weinshenker BG. Identifying disease modifying genes in multiple sclerosis. J Neuroimmunol. 2002;123:144-159.
116. Zhou Q, Rammohan K, Lin S, et al. CD24 is a genetic modifier for risk and progression of multiple sclerosis. Proc Natl Acad Sci U S A. 2003;100:15041-15046.
117. Kikuchi S, Fukazawa T, Niino M, et al. Estrogen receptor gene polymorphism and multiple sclerosis in Japanese patients: interaction with HLA-DRB 1 * 1501 and disease modulation. J Neuroimmunol. 2002;128:77-81.
118. Mattila KM, Luomala M, Lehtimaki T, Laippala P, Koivula T, Elovaara I. Interaction between ESR1 and HLA-DR2 may contribute to the development of MS in women. Neurology. 2001;56:1246-1247.
119. Kantarci OH, Hebrink DD, Achenbach SJ, et al. CD95 polymorphisms are associated with susceptibility to MS in women: a population-based study of CD95 and CD95L in MS. J Neuroimmunol. 2004;146:162-170.
120. Giess R, Maurer M, Linker R, et al. Association of a null mutation in the CNTF gene with early onset of multiple sclerosis. Arch Neurol. 2002;59:407-409.
121. Hoffmann V, Hardt C. A null mutation in the CNTF gene is not associated with early onset of multiple sclerosis. Arch Neurol. 2002;59:1974.
122. Hoffmann V, Pohlau D, Przuntek H, Epplen JT, Hardt C. A null mutation within the ciliary neurotrophic factor (CNTF)-gene: implications for susceptibility and disease severity in patients with multiple sclerosis. Genes Immun. 2002;3:53-55.
123. van Veen T, van Winsen L, Crusius JB, et al. [Alpha]B-crystallin genotype has impact on the multiple sclerosis phenotype. Neurology. 2003;61:1245-1249.
124. Shinar Y, Livneh A, Villa Y, et al. Common mutations in the familial Mediterranean fever gene associate with rapid progression to disability in non-Ashkenazi Jewish multiple sclerosis patients. Genes Immun. 2003;4:197-203.
125. Evangelou N, Jackson M, Beeson D, Palace J. Association of the APOE epsilon4 allele with disease activity in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1999;67:203-205.
126. Fazekas F, Strasser-Fuchs S, Schmidt H, et al. Apolipoprotein E genotype related differences in brain lesions of multiple sclerosis. J Neurol Neurosurg Psychiatry. 2000;69:25-28.
127. Hogh P, Oturai A, Schreiber K, et al. Apoliprotein E and multiple sclerosis: impact of the epsilon-4 allele on susceptibility, clinical type and progression rate. Mult Scler. 2000;6:226-230.
128. Chapman J, Vinokurov S, Achiron A, et al. APOE genotype is a major predictor of long-term progression of disability in MS. Neurology. 2001;56:312-316.
129. Fazekas F, Strasser-Fuchs S, Kollegger H, et al. Apolipoprotein E epsilon 4 is associated with rapid progression of multiple sclerosis. Neurology. 2001;57:853-857.
130. Enzinger C, Ropele S, Smith S, et al. Accelerated evolution of brain atrophy and "black holes" in MS patients with APOE-epsilon 4. Ann Neurol. 2004;55:563-569.
131. Ferri C, Sciacca FL, Veglia F, et al. APOE epsilon2-4 and -491 polymorphisms are not associated with MS. Neurology. 1999;53:888-889.
132. Weatherby SJ, Mann CL, Fryer AA, et al. No association between the APOE epsilon4 allele and outcome and susceptibility in primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2000;68:532.
133. Masterman T, Zhang Z, Hellgren D, et al. APOE genotypes and disease severity in multiple sclerosis. Mult Scler. 2002;8:98-103.
134. Savettieri G, Andreoli V, Bonavita S, et al. Apolipoprotein E genotype does not influence the progression of multiple sclerosis. J Neurol. 2003;250:1094-1098.
135. Ballerini C, Campani D, Rombola G, et al. Association of apolipoprotein E polymorphism to clinical heterogeneity of multiple sclerosis. Neurosci Lett. 2000;296:174-176.
136. Schmidt S, Barcellos LF, DeSombre K, et al. Association of polymorphisms in the apolipoprotein E region with susceptibility to and progression of multiple sclerosis. Am J Hum Genet. 2002;70:708-717.
137. Kantarci OH, Hebrink DD, Achenbach SJ, et al. Association of APOE polymorphisms with disease severity in MS is limited to women. Neurology. 2004;62:811-814.
138. Green AJ, Barcellos LF, Rimmler JB, et al. Sequence variation in the transforming growth factor-betal (TGFB1) gene and multiple sclerosis susceptibility. J Neuroimmunol. 2001;116:116-124.
139. Barcellos LF, Oksenberg JR, Begovich AB, et al. HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. Am J Hum Genet. 2003;72:710-716.
140. Garcia-Merino A, Alper CA, Usuku K, et al. Tumor necrosis factor microsatellite haplotypes in relation to extended haplotypes, susceptibility to diseases associated with the major histocompatibility complex, and TNF secretion. Hum Immunol. 1996;50:11-21.